<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734916</url>
  </required_header>
  <id_info>
    <org_study_id>GW/MV/20307</org_study_id>
    <secondary_id>CMO 2008/140</secondary_id>
    <nct_id>NCT00734916</nct_id>
  </id_info>
  <brief_title>Immune Modulation by Parenteral Lipids</brief_title>
  <official_title>Immune Modulation by Omega-3 Versus Omega-6 Based Parenteral Lipids in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune modulating properties of parenteral lipid emulsions seem to contribute to the
      increased risk for infections which remains associated with the use of total parenteral
      nutrition. Emulsions based on soy bean oil (SO) are the oldest and still most widely used
      lipid source in TPN formulations but their high content of omega-6 polyunsaturated fatty
      acids (PUFAs) may be a drawback. Fish oil-based lipid emulsions (FO), rich in omega-3 PUFAs,
      has been approved for parenteral nutrition in many countries. Mainly retrospective studies on
      clinical outcomes in septic and postoperative patients have suggested clinical benefits with
      the inclusion of FO in parenteral nutrition regimens. The exact mechanisms behind the
      beneficial immunological effects of parenteral FO have, however, not yet been elucidated.

      Objective:

      To evaluate the effects of intravenous infusion of a FO-based lipid emulsion and a SO-based
      emulsion on immune function as evidenced by effects on peripheral blood leukocyte counts and
      functions and on the susceptibility to oxidative stress.

      Study design:

      Randomized placebo controlled cross-over pilot study with healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>leukocyte counts</measure>
    <time_frame>T=0, T=4 days, T=11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>leukocyte functions</measure>
    <time_frame>T=0, T=4 days and T=11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(anti-)oxidant status</measure>
    <time_frame>T=0, T=4 days, T=11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma and leukocyte cell membrane (phospho)lipid composition.</measure>
    <time_frame>T=0, t=4 and T=11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Infections</condition>
  <condition>Total Parenteral Nutrition</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omegaven 10%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intralipid 10%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Parenteral lipid emulsion (Omegaven)</intervention_name>
    <description>Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Omegaven 10%, Fresenius Kabi, Bad Homburg Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Parenteral lipid emulsion (Intralipid)</intervention_name>
    <description>Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Intralipid 10%, Fresenius Kabi, Bad Homburg Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Parental lipid emulsion (Saline 0.9%)</intervention_name>
    <description>Placebo (Saline 0.9%), same volume/hr as lipid emulsions</description>
    <arm_group_label>3</arm_group_label>
    <other_name>lipid free control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt;18 yrs of age)

          -  Healthy

          -  Willingness to give written informed consent

        Exclusion Criteria:

          -  Smoking &gt; 5 cigarettes/day

          -  Diet with &gt; 2 portions of fatty fish per day

          -  Use of oral fish oil or vitamin substrates

          -  History of metabolic disorder (especially diabetes or lipid disorders)

          -  History of allergic, inflammatory of immunological disease

          -  History of pulmonary, cardiovascular, renal or hematological disease

          -  Medication use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert JA Wanten, MD, MSc, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>M.W.J. Versleijen, MD, MSc and G.J.A. Wanten, MD, MSc, PhD</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <keyword>total parenteral nutrition</keyword>
  <keyword>infections</keyword>
  <keyword>Infectious complications related to parenteral nutrition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

